Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis.

Abstract

Recombinant human interleukin-11 (rhIL-11) has been shown to increase platelet counts in animals and humans and is the only drug approved for its use in chemotherapy-induced thrombocytopenia (CIT). However, due to its serious side effects, its clinical use has been limited. The current work presents significantly improved efficacy of rhIL-11 via knowledge… (More)
DOI: 10.1016/j.bbrc.2011.01.041

Topics

Cite this paper

@article{Jung2011ImprovementOB, title={Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis.}, author={Yuni Jung and Haesook Ahn and Dong-Sik Kim and Yu Ri Hwang and Seong-Hyun Ho and Jong-Mook Kim and Sunyoung Kim and Suyong Ma}, journal={Biochemical and biophysical research communications}, year={2011}, volume={405 3}, pages={399-404} }